Sort
21,281 grants matching “influenza”
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma
$871,073John H Sampson · Duke University · U01 · FY2019 · NS
Modulation of Viral Antigen Presentation in the Lung
$870,979Anna Karolina Palucka · Jackson Laboratory · U19 · FY2023 · AI
Ex vivo interrogation of the genetic and biochemical networks controlling influe
$870,905Megan Louise Shaw · Icahn School Of Medicine At Mount Sinai · U19 · FY2015 · AI
Balancing epithelial cell resistance and resilience to respiratory viral infections
$869,852Jose Manuel Ordovas-Montanes · Boston Children'S Hospital · R01 · FY2023 · HL
Development of Aersolized Vaccines
$869,351Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Genetic Investigation of Covid 19 in Lung Disease
$869,001Mark L Kahn · University Of Pennsylvania · R01 · FY2024 · HL
Marketing Workplace Chronic Disease Prevention
$868,967Kyle Harris · University Of Washington · P01 · FY2007 · CD
Nucleic Acid Dipstick for Rapid Avian Flu Detection at Point-of-care
$868,356Hong Cai · Los Alamos Nat Secty-Los Alamos Nat Lab · R01 · FY2008 · AI
Genomic Regulatory Networks in Innate Immune Cells
$868,180Whitehead Institute For Biomedical Res · R01 · FY2004 · AI
Activated Sugars, Oligosaccharides and Glycans for Antiviral Research
$868,039Leila Aminova · Midwest Bioprocessing Center, Llc · R44 · FY2022 · GM
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$867,817Richard Rothman · Johns Hopkins University · N01 · FY2018 · AI
Phylodynamics of emerging infectious disease threats
$867,681Martha Nelson · National Library Of Medicine · ZIA · FY2024 · LM
Countermeasures for Bioterroism Targeting Cellular Host Factors
$867,102John C Reed · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2011 · AI
Function and Differentiation
$866,753Marion Pepper · University Of Washington · R56 · FY2023 · AI
Text4Vax: Understanding the Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines
$866,647Melissa S Stockwell · Columbia University Health Sciences · R01 · FY2024 · AI
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
$865,920Ann R Falsey · University Of Rochester · UM1 · FY2025 · AI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
$865,457Stefanie N. Vogel · University Of Maryland Baltimore · R01 · FY2015 · AI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
$865,457Stefanie N. Vogel · University Of Maryland Baltimore · R01 · FY2016 · AI
Regulation of primary and secondary CD4 and CD8 T cell memory
$865,408John T. Harty · University Of Iowa · R37 · FY2017 · AI
Immune Dysfunction in HIV+ Opioid Users
$865,279Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2024 · DA
Structure-Function of Heavy Metal Transport CPx-ATPases
$865,148Jose M Arguello · Worcester Polytechnic Institute · · FY2003 · BIO
Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza
$864,948Gregory Davenport · Tff Pharmaceuticals, Inc. · R44 · FY2023 · AI
Avian Influenza Surveillance in Thailand-Studies at Human-Animal Interface
$864,906Pilaipan Puthavathana · Mahidol University · U19 · FY2008 · CI
CD4+ T cell epitopes for Clostridium tetani, influenza and Bacillus anthracis
$864,889Benaroya Research Inst At Virginia Mason · N01 · FY2008 · AI
Development of vaccination strategies to elicit broadly protective immunity against influenza
$864,833Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2019 · AI